Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

healthcare money economics dollar stethoscope acquire merger

Novartis to acquire drugmaker behind new heart therapy for up to $3.1B

The FDA has already shown great interest in the drug, which is designed to help AFib patients reduce their stroke and systemic embolism risks.

Cardiologist heart

Treating a broken heart: Beta-blockers improve survival in patients with takotsubo syndrome

Takotsubo syndrome, commonly known as “broken heart syndrome,” is often treated as if it was heart failure, but the optimal clinical approach remains a bit of a mystery.

heart surgery cardiac surgeons

Benzodiazepine use before heart surgery: Should it be embraced or restricted?

Benzodiazepines are administered before a majority of cardiac surgeries to lower the risk of intraoperative awareness. At the same time, however, recent studies have suggested they increase the risk of postoperative delirium.

Thumbnail

Nearly half of U.S. adults are wrong about aspirin

Cardiologists have warned for years that healthy adults with no family history of CVD should not be taking low-dose aspirin every day—but as the saying goes, old habits die hard. 

Thumbnail

Blood pressure drug recalled due to black contaminants—FDA highlights safety risks

The recall was put in place after a customer discovered “visible black particulate matter” in a sealed vial. If the contaminant enters a patient's blood vessels, it could lead to serious complications, including a stroke or even death. 

money maze payment reimbursement

Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

Video of Clyde Yancy, MD, explaining new directions in treating heart failure with preserved ejection fraction.

Exploring the 'new era' of HFpEF treatment: More options exist, but challenges remain

Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.

Semaglutide linked to ‘significant and consistent’ benefits for heart bypass surgery patients

The popular GLP-1 receptor agonist appears to help limit adverse events and new-onset diabetes in patients with a history of CABG. Researchers shared the full study in the Journal of the American College of Cardiology.